Zhang A Z, Zhou G Z, Xi G F, Gu N F, Xia Z Y, Yao J L, Chang J K, Webber R, Potkin S
Neuropeptides. 1985 Feb;5(4-6):553-6. doi: 10.1016/0143-4179(85)90077-0.
Using a highly specific and sensitive radioimmunoassay for dynorphin(1-8) (D 1-8), and a singly blind test design, we measured D(1-8) immunoreactivity (ir D 1-8) in CSF of 35 first break cases of acute schizophrenic patients. All patients were free of psychotropic medication for at least one week before the study. Another 31 neurological patients suffered from cervical arthrosis, tumor, myelopathy etc. were studied as controls. The ir D(1-8) in CSF of schizophrenic patients were significantly lower than that of controls (91.8 +/- 5.6, means +/- S.E.M., and 131.9 +/- 6.8 fmol/ml CSF respectively, p less than 0.001).
我们采用针对强啡肽（1-8）（D 1-8）的高特异性和高灵敏度放射免疫分析法，并运用单盲试验设计，对35例急性精神分裂症首次发病患者的脑脊液中D（1-8）免疫反应性（ir D 1-8）进行了测量。所有患者在研究前至少一周未服用精神药物。另外31例患有颈椎病、肿瘤、脊髓病等的神经科患者作为对照进行研究。精神分裂症患者脑脊液中的ir D（1-8）显著低于对照组（分别为91.8±5.6、均值±标准误，以及131.9±6.8 fmol/ml脑脊液，p<0.001）。
